Go to the list of all blogs
Arthur Evans's Avatar
published in Blogs
Jul 23, 2026
TickeronGET DAILY SIGNALS
CME Group (CME) Beats Estimates and Sees Shares Climb +6%

CME Group (CME) Beats Estimates and Sees Shares Climb +6%

Key Takeaways

  • Revenue reached a second-quarter record of $1.71 billion, up approximately 1% year-over-year and edging past the Wall Street consensus estimate of roughly $1.68 billion to $1.70 billion.
  • Adjusted diluted earnings per share (EPS) came in at $2.99, comfortably ahead of analyst forecasts that ranged from $2.91 to $2.98, while GAAP (Generally Accepted Accounting Principles) EPS was $2.88.
  • Market data revenue surged 20% to a record $238 million, marking 33 consecutive quarters of year-over-year growth and helping offset a modest decline in clearing and transaction fee revenue.
  • Average daily volume (ADV) of 29.8 million contracts represented the second-highest second quarter in company history, even as it slipped about 1% from the prior-year period.
  • CME returned $1.2 billion to shareholders through $468 million in dividends and $695 million in share repurchases, underscoring the company's commitment to capital returns.
  • Shares jumped more than 6% following the release, as investors focused on the earnings beat and resilient demand across key product categories.

Putting the Earnings in Context

CME Group entered the second quarter under a cloud of investor anxiety. Since May, when regulators approved cryptocurrency perpetual futures at rival platform Kalshi, CME stock had tumbled roughly 19% on fears that never-expiring contracts could chip away at the company's traditional futures franchise. Against that backdrop, the Q2 2026 report served as a critical test of CME's ability to sustain its institutional dominance and pricing power. The results — featuring record second-quarter revenue, an adjusted EPS beat, and historically strong market data performance — helped calm nerves. With ADV (average daily volume) holding near all-time highs and July volume already tracking 18% above last year, the quarter reinforced the view that CME's diversified product portfolio and deep institutional client base remain powerful competitive moats.

Breaking Down the Reported Results

When CME Group reported second-quarter 2026 revenue of approximately $1.71 billion, it marked a modest increase from the $1.69 billion recorded in Q2 2025 and came in slightly above the consensus analyst estimate. Adjusted diluted EPS landed at $2.99, outperforming the $2.91 to $2.98 range that analysts had projected and edging ahead of the $2.96 posted a year ago. On a GAAP basis, net income was $1.04 billion, or $2.88 per share. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

The revenue mix reflected a subtle but important shift. Clearing and transaction fee revenue — the company's traditional core — declined roughly 2.6% year-over-year to $1.35 billion, pressured by softer trading activity in interest rate and energy derivatives. However, market data and information services revenue surged 20% to an all-time quarterly high of $238 million, continuing a remarkable streak of 33 consecutive quarters of year-over-year growth. The total average rate per contract rose to $0.678, a $0.026 sequential increase from Q1 2026, signaling favorable pricing dynamics.

ADV came in at 29.8 million contracts, down about 1% from the prior-year quarter but still the third-highest quarterly ADV on record and the second-best second quarter in CME's history. Equity index ADV jumped 13% year-over-year, agricultural contracts rose 6%, and cryptocurrency volumes also posted gains, while interest rate and energy ADV softened.

Adjusted operating income reached $1.2 billion, translating to a 69.5% adjusted operating margin, while the adjusted net income margin stood at 63.4% — figures that underscore the exchange's exceptional profitability. CME also highlighted a new record in capital efficiencies, saving customers an average of more than $95 billion in margin per day during the quarter.

How the Market Reacted

The market responded enthusiastically to CME Group's second-quarter report, sending shares up more than 6% in the trading session that followed the release. The rally helped recover a portion of the stock's year-to-date losses and signaled that investors were willing to look past the perpetual futures narrative that had weighed on sentiment for weeks. Analysts at Piper Sandler characterized the quarter as "solid," noting that difficult year-over-year volume comparisons made the revenue achievement all the more notable. The combination of an EPS beat, record market data revenue, and strong July volume guidance appeared to re-anchor investor focus on CME's fundamental strengths — its dominant institutional client base, pricing power, and product innovation pipeline — rather than the competitive headlines that had dominated the prior two months.

Exploring Broader Opportunities with AI Tools

Investors looking to identify market opportunities beyond single-stock analysis may find value in Tickeron's AI Screener. The AI Screener is an AI-powered stock and ETF (exchange-traded fund) discovery tool that allows traders and investors to filter the market using a wide range of customizable criteria, including technical patterns, fundamental metrics, volatility profiles, and AI-driven signals. Users can scan thousands of securities by industry, market capitalization, technical indicators, price patterns, and performance metrics, helping to surface trade ideas, trending stocks, breakout candidates, and emerging market themes more efficiently than traditional manual screening. For those monitoring earnings seasons and sector rotations, the AI Screener offers a practical way to stay ahead of shifting market dynamics. I’ve found it helpful for quickly comparing CME against peers during volatile periods like this one.

What to Watch Going Forward

Looking ahead, several factors will shape CME Group's trajectory through the second half of 2026 and into 2027. The most immediate positive signal came from management's disclosure that July-to-date volumes are running 18% above the prior-year period, suggesting that the modest ADV softness observed in Q2 may prove temporary.

Product innovation remains a central theme. CME is moving forward with several initiatives, including the launch of single-stock futures and 24/7 trading of crypto futures, as well as the planned introduction of TreasuryLink — a platform designed to connect U.S. Treasury futures with cash Treasury liquidity pools. These offerings could drive incremental volume growth and diversify the revenue base further, though regulatory approvals and market adoption will dictate their impact.

The competitive landscape, particularly around perpetual futures, will continue to draw scrutiny. CME has taken legal action against the CFTC (Commodity Futures Trading Commission) over what it describes as "competitive injury" from the approval of perpetual futures at rival venues. The resolution of this dispute — whether through the courts, regulatory adjustments, or market-driven outcomes — has the potential to influence the long-term competitive dynamics of the derivatives industry.

Leadership transition is another factor to monitor. In June, CME announced that CEO Terry Duffy will transition to the role of Executive Chairman in March 2027, with President and CFO Lynne Fitzpatrick set to take the helm. The succession plan introduces a period of executive-level change, though the early announcement and internal promotion suggest a deliberate and orderly handover.

Finally, capital allocation remains a bright spot. With $2.3 billion in cash on the balance sheet and a demonstrated willingness to return capital aggressively — $1.2 billion in Q2 alone through dividends and buybacks — CME continues to reward shareholders while maintaining the flexibility to invest in growth. Investors will watch whether the pace of buybacks continues and whether market data revenue can sustain its multi-year growth streak as the macroeconomic backdrop evolves.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CME

Contributor

Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.


CME saw its Stochastic Oscillator peaks and leaves the overbought zone

The Stochastic Oscillator for CME moved out of overbought territory on November 18, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 68 similar instances where the indicator exited the overbought zone. In 30 of the 68 cases the stock moved lower. This puts the odds of a downward move at 44%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for CME moved out of overbought territory on November 17, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 40 similar instances where the indicator moved out of overbought territory. In 16 of the 40 cases, the stock moved lower in the following days. This puts the odds of a move lower at 40%.

The Moving Average Convergence Divergence Histogram (MACD) for CME turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 19 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 41%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CME declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 42%.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on November 20, 2026. You may want to consider a long position or call options on CME as a result. In 64 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 61%.

Following a +1.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where CME advanced for three days, in 174 of 343 cases, the price rose further within the following month. The odds of a continued upward trend are 51%.

The Aroon Indicator entered an Uptrend today. In 137 of 259 cases where CME Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 53%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 31 (best 1 - 100 worst), indicating outstanding price growth. CME’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 32 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 76, placing this stock better than average.

The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is 54 (best 1 - 100 worst), indicating slightly weaker than average sales and a marginally profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.147) is normal, around the industry mean (4.143). P/E Ratio (25.814) is within average values for comparable stocks, (19.659). CME's Projected Growth (PEG Ratio) (4.578) is very high in comparison to the industry average of (1.780). Dividend Yield (0.017) settles around the average of (0.017) among similar stocks. CME's P/S Ratio (14.535) is slightly higher than the industry average of (7.166).

Notable companies

The most notable companies in this group are CME Group (NASDAQ:CME).

Industry description

The financial publishing /services sector includes companies that provide informational products and services that are of value to investors, financial/analytics professionals and other interested readers. The products include real-time stock quotes, financial news and analyses. Think S&P Global, Inc., Moody`s Corporation, Thomson-Reuters Corp and IHS Markit Ltd. Information is critical in making financial or investment decisions, and what makes this industry’s output relevant at all times, across various economic conditions.

Market Cap

The average market capitalization across the Financial Publishing/Services Industry is 46.28B. The market cap for tickers in the group ranges from 1.27M to 137.91B. SPGI holds the highest valuation in this group at 137.91B. The lowest valued company is BTOG at 1.27M.

High and low price notable news

The average weekly price growth across all stocks in the Financial Publishing/Services Industry was -7%. For the same Industry, the average monthly price growth was -3%, and the average quarterly price growth was 3%. DTCX experienced the highest price growth at 3%, while COIN experienced the biggest fall at -20%.

Volume

The average weekly volume growth across all stocks in the Financial Publishing/Services Industry was 56%. For the same stocks of the Industry, the average monthly volume growth was 10% and the average quarterly volume growth was 7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 80
P/E Growth Rating: 49
Price Growth Rating: 44
SMR Rating: 52
Profit Risk Rating: 75
Seasonality Score: 30 (-100 ... +100)
AI Screener 4
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an operator of securities and commodity exchanges

Industry FinancialPublishingServices

Industry
Investment Banks Or Brokers
Address
20 South Wacker Drive
Phone
+1 312 930-1000
Employees
3875
Web
https://www.cmegroup.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.